{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:06:53Z","timestamp":1772831213619,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with idiopathic inflammatory myopathy (IIM) often express a different type of myositis-specific autoantibodies (MSAs), each associated with different clinical symptoms. Understanding the immunopathogenesis of various IIM subgroups can help improve the diagnosis and prognosis of IIM patients with different MSAs. However, the immune cell profiles of these IIM patients with anti-aminoacyl tRNA synthetase (ARS) or anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies remain unclear. We focused on the immune cell profiles of IIM patients with anti-ARS or anti-MDA5 autoantibodies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The peripheral blood from IIM patients with anti-MDA5 autoantibody (MDA5\u2009+\u2009group, <jats:italic>n<\/jats:italic>\u2009=\u200924) or one of the anti-ARS autoantibodies (ARS\u2009+\u2009group, <jats:italic>n<\/jats:italic>\u2009=\u200940) autoantibodies, and healthy controls (HC group, <jats:italic>n<\/jats:italic>\u2009=\u200960) were collected and examined. We found that IIM patients had a lower CD3 T cell population compared to the HC group. IIM patients showed a significantly lower T<jats:sub>N<\/jats:sub> cell population and a higher T<jats:sub>EMRA<\/jats:sub> cell population. Higher Th17 and Treg cell populations were found in these IIM patients than in the HC group. In these IIM patients, the MDA5\u2009+\u2009group exhibited the higher percentages of Th17 and Treg cells than the ARS\u2009+\u2009group. It is noteworthy that the percentage of Th1 cells in the survival subgroup was higher than in the death subgroup in IIM patients with ARS\u2009+\u2009or MDA5\u2009+\u2009. Furthermore, in the MDA5\u2009+\u2009group, the percentage of Treg cells was higher in the survival subgroup compared to the death subgroup.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study demonstrated that elevated Th1 may be a good prognostic indicator in IIM patients with ARS\u2009+\u2009or MDA5\u2009+\u2009. Elevated Treg may also help predict a good prognosis in MDA5\u2009+\u2009IIM patients. However, more large-scale studies and clinical samples are needed to verify the significance of Th1 and Treg cell subsets in clinical outcomes for these IIM patients with ARS\u2009+\u2009or MDA5\u2009+\u2009. These data may help design a therapeutic approach that specifically targets the pathogenic immune molecular responsible for autoimmune attacks in IIM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12865-023-00569-w","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T13:02:37Z","timestamp":1695733357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune cell profiles of idiopathic inflammatory myopathy patients expressed anti-aminoacyl tRNA synthetase or anti-melanoma differentiation-associated gene 5 autoantibodies"],"prefix":"10.1186","volume":"24","author":[{"given":"Joung-Liang","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Tsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hua","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Pi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"569_CR1","unstructured":"Cheeti A, Brent LH, Panginikkod S: Autoimmune Myopathies. In: StatPearls. edn. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC.; 2023."},{"key":"569_CR2","unstructured":"Sarwar A, Dydyk AM, Jatwani S. Polymyositis. In: StatPearls.\u00a0edn.\u00a0Treasure Island (FL): StatPearls Publishing LLC; 2023.\u00a0StatPearls Publishing Copyright\u00a0\u00a9\u00a02023."},{"key":"569_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cca.2015.02.007","volume":"444","author":"X Lu","year":"2015","unstructured":"Lu X, Peng Q, Wang G. Discovery of new biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta. 2015;444:117\u201325.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"569_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.autrev.2015.01.017","volume":"14","author":"J Damoiseaux","year":"2015","unstructured":"Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev. 2015;14(6):555\u201363.","journal-title":"Autoimmun Rev"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fneur.2019.00438","volume":"10","author":"B Stuhlm\u00fcller","year":"2019","unstructured":"Stuhlm\u00fcller B, Schneider U, Gonz\u00e1lez-Gonz\u00e1lez J-B, Feist E. Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies. Front Neurol. 2019;10:438.","journal-title":"Front Neurol."},{"issue":"4","key":"569_CR6","first-page":"151","volume":"34","author":"J-P Li","year":"2022","unstructured":"Li J-P. Idiopathic Inflammatory Myopathy and the COVID-19 Pandemic. J Biomed Lab Sci. 2022;34(4):151\u20138.","journal-title":"J Biomed Lab Sci"},{"issue":"12","key":"569_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, et al. 2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017;69(12):2271\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"569_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"569_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12948-018-0084-9","volume":"16","author":"B Palterer","year":"2018","unstructured":"Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P. Bench to bedside review of myositis autoantibodies. Clin Mole Allergy. 2018;16(1):5.","journal-title":"Clin Mole Allergy"},{"key":"569_CR10","first-page":"290","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL. Autoantibodies in myositis. Nature Reviews. Rheumatology. 2018;14:290.","journal-title":"Rheumatology"},{"issue":"6","key":"569_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70(6):360\u201374.","journal-title":"Medicine"},{"issue":"7","key":"569_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/art.1780350718","volume":"35","author":"IN Targoff","year":"1992","unstructured":"Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl\u2013transfer rna synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992;35(7):821\u201330.","journal-title":"Arthritis Rheum"},{"key":"569_CR13","doi-asserted-by":"publisher","first-page":"1029218","DOI":"10.3389\/fphys.2022.1029218","volume":"13","author":"AK Turvey","year":"2022","unstructured":"Turvey AK, Horvath GA, Cavalcanti ARO. Aminoacyl-tRNA synthetases in human health and disease. Front Physiol. 2022;13:1029218.","journal-title":"Front Physiol"},{"issue":"6","key":"569_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s100670050139","volume":"18","author":"M Ito","year":"1999","unstructured":"Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, Nishimaki T, Nakamura N, Kasukawa R. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18(6):462\u20137.","journal-title":"Clin Rheumatol"},{"issue":"16","key":"569_CR15","doi-asserted-by":"publisher","first-page":"26552","DOI":"10.18632\/oncotarget.15716","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, Wang Q, Yang F, Wu C, Chen S, Wen X, Liu C, Li Y. Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. Oncotarget. 2017;8(16):26552\u201364.","journal-title":"Oncotarget"},{"key":"569_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 antibodies: Bioclinical features pathogenesis and emerging. Therapies Front Immunol. 2021;12: 773352.","journal-title":"Therapies Front Immunol"},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","volume":"14","author":"FW Miller","year":"2018","unstructured":"Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14:255.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"569_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/BOR.0000000000000831","volume":"33","author":"C Franco","year":"2021","unstructured":"Franco C, Gatto M, Iaccarino L, Ghirardello A, Doria A. Lymphocyte immunophenotyping in inflammatory myositis: a review. Curr Opin Rheumatol. 2021;33(6):522\u20138.","journal-title":"Curr Opin Rheumatol."},{"key":"569_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.756018","volume":"13","author":"EM Wilfong","year":"2022","unstructured":"Wilfong EM, Bartkowiak T, Vowell KN, Westlake CS, Irish JM, Kendall PL, Crofford LJ, Bonami RH. High-dimensional analysis reveals distinct endotypes in patients with idiopathic inflammatory myopathies. Front Immunol. 2022;13: 756018.","journal-title":"Front Immunol"},{"issue":"1","key":"569_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-020-02412-8","volume":"23","author":"J Young-Glazer","year":"2021","unstructured":"Young-Glazer J, Cisneros A 3rd, Wilfong EM, Smith SA, Crofford LJ, Bonami RH. Jo-1 autoantigen-specific B cells are skewed towards distinct functional B cell subsets in anti-synthetase syndrome patients. Arthritis Res Ther. 2021;23(1):33.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"569_CR21","first-page":"194","volume":"59","author":"MGL Wilkinson","year":"2020","unstructured":"Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, Jury EC. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. Rheumatology (Oxford). 2020;59(1):194\u2013204.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"569_CR22","first-page":"1178","volume":"146","author":"JL De Bleecker","year":"1995","unstructured":"De Bleecker JL, Engel AG. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol. 1995;146(5):1178\u201387.","journal-title":"Am J Pathol"},{"issue":"6","key":"569_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/ar4116","volume":"14","author":"V Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m V, Venalis P, Albrecht I. T cells in myositis. Arthritis Res Ther. 2012;14(6):230.","journal-title":"Arthritis Res Ther"},{"issue":"20","key":"569_CR24","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.3390\/cells11203330","volume":"11","author":"C Nelke","year":"2022","unstructured":"Nelke C, Pawlitzki M, Schroeter CB, Huntemann N, R\u00e4uber S, Dobelmann V, Preusse C, Roos A, Allenbach Y, Benveniste O, et al. High-dimensional cytometry dissects immunological fingerprints of idiopathic inflammatory myopathies. Cells. 2022;11(20):3330.","journal-title":"Cells"},{"issue":"1","key":"569_CR25","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X, Xue J, Lian X, Ma J, Hao P, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun. 2022;13(1):6458.","journal-title":"Nat Commun"},{"issue":"1_Supplement","key":"569_CR26","doi-asserted-by":"publisher","first-page":"182.134","DOI":"10.4049\/jimmunol.202.Supp.182.34","volume":"202","author":"J-P Li","year":"2019","unstructured":"Li J-P, Chang S-H, Tsay GJ, Chen D-Y, Lan J-L. Idiopathic inflammatory myopathy patients with different autoantibody exhibit unique peripheral blood T cell subsets. J Immunol. 2019;202(1_Supplement):182.134\u2013182.134.","journal-title":"J Immunol"},{"issue":"6","key":"569_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/ni.2038","volume":"12","author":"M Pepper","year":"2011","unstructured":"Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol. 2011;12(6):467\u201371.","journal-title":"Nat Immunol"},{"issue":"2","key":"569_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.smim.2009.02.006","volume":"21","author":"MKL MacLeod","year":"2009","unstructured":"MacLeod MKL, Clambey ET, Kappler JW, Marrack P. CD4 memory T cells: What are they and what can they do? Semin Immunol. 2009;21(2):53\u201361.","journal-title":"Semin Immunol"},{"issue":"1","key":"569_CR29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: Function generation, and maintenance. Annu Rev Immunol. 2004;22(1):745\u201363.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"569_CR30","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2002-11-3577","volume":"101","author":"J Geginat","year":"2003","unstructured":"Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood. 2003;101(11):4260\u20136.","journal-title":"Blood"},{"issue":"6754","key":"569_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708\u201312.","journal-title":"Nature"},{"issue":"6","key":"569_CR32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/eji.202149465","volume":"52","author":"N Heikkil\u00e4","year":"2022","unstructured":"Heikkil\u00e4 N, Hetem\u00e4ki I, Sormunen S, Isoniemi H, Kek\u00e4l\u00e4inen E, Saram\u00e4ki J, Arstila TP. Peripheral differentiation patterns of human T cells. Eur J Immunol. 2022;52(6):882\u201394.","journal-title":"Eur J Immunol"},{"issue":"2","key":"569_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity. 2018;48(2):202\u201313.","journal-title":"Immunity"},{"key":"569_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1146\/annurev.immunol.18.1.593","volume":"18","author":"F Sallusto","year":"2000","unstructured":"Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593\u2013620.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"569_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/84205","volume":"2","author":"SA Luther","year":"2001","unstructured":"Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol. 2001;2(2):102\u20137.","journal-title":"Nat Immunol"},{"key":"569_CR36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745\u201363.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"569_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3158","volume":"12","author":"HT Maecker","year":"2012","unstructured":"Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat Rev Immunol. 2012;12(3):191\u2013200.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"569_CR38","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","volume":"13","author":"M Noack","year":"2014","unstructured":"Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13(6):668\u201377.","journal-title":"Autoimmun Rev"},{"key":"569_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri.2017.75","volume":"17","author":"L Lu","year":"2017","unstructured":"Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;17:703.","journal-title":"Nat Rev Immunol"},{"issue":"21","key":"569_CR40","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325(21):1487\u201398.","journal-title":"N Engl J Med"},{"issue":"9388","key":"569_CR41","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971\u201382.","journal-title":"Lancet"},{"issue":"18","key":"569_CR42","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734\u201347.","journal-title":"N Engl J Med"},{"key":"569_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fneur.2016.00064","volume":"7","author":"A Malik","year":"2016","unstructured":"Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: Clinical approach and management. Front Neurol. 2016;7:64.","journal-title":"Front Neurol"},{"key":"569_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrrheum.2017.1","volume":"13","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE. New tools for diagnosis and therapy. Nat Rev Rheumatol. 2017;13:74.","journal-title":"Nat Rev Rheumatol"},{"issue":"1\u20133","key":"569_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12026-013-8448-1","volume":"57","author":"P Devarajan","year":"2013","unstructured":"Devarajan P, Chen Z. Autoimmune effector memory T cells: the bad and the good. Immunol Res. 2013;57(1\u20133):12\u201322.","journal-title":"Immunol Res"},{"issue":"7","key":"569_CR46","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1002\/art.21943","volume":"54","author":"RD Fritsch","year":"2006","unstructured":"Fritsch RD, Shen X, Illei GG, Yarboro CH, Prussin C, Hathcock KS, Hodes RJ, Lipsky PE. Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthritis Rheum. 2006;54(7):2184\u201397.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"569_CR47","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/ar1703","volume":"7","author":"A Skapenko","year":"2005","unstructured":"Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Ther. 2005;7(2):S4.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"569_CR48","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1093\/brain\/awz207","volume":"142","author":"SA Greenberg","year":"2019","unstructured":"Greenberg SA, Pinkus JL, Kong SW, Baecher-Allan C, Amato AA, Dorfman DM. Highly differentiated cytotoxic T cells in inclusion body myositis. Brain. 2019;142(9):2590\u2013604.","journal-title":"Brain"},{"issue":"3","key":"569_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cyto.2009.02.013","volume":"46","author":"A Tournadre","year":"2009","unstructured":"Tournadre A, Porcherot M, Ch\u00e9rin P, Marie I, Hachulla E, Miossec P. Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine. 2009;46(3):297\u2013301.","journal-title":"Cytokine"},{"issue":"1 Suppl","key":"569_CR50","first-page":"e589","volume":"128","author":"M Kondo","year":"2009","unstructured":"Kondo M, Murakawa Y, Harashima N, Kobayashi S, Yamaguchi S, Harada M. Roles of proinflammatory cytokines and the Fas\/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology. 2009;128(1 Suppl):e589\u2013599.","journal-title":"Immunology"},{"key":"569_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/345347","volume":"2013","author":"X Tang","year":"2013","unstructured":"Tang X, Tian X, Zhang Y, Wu W, Tian J, Rui K, Tong J, Lu L, Xu H, Wang S. Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol. 2013;2013: 345347.","journal-title":"Clin Dev Immunol"},{"issue":"1\u20132","key":"569_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jneuroim.2010.03.013","volume":"225","author":"A Waschbisch","year":"2010","unstructured":"Waschbisch A, Schwab N, Ruck T, Stenner MP, Wiendl H. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol. 2010;225(1\u20132):137\u201342.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"569_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088788","volume":"9","author":"Y Allenbach","year":"2014","unstructured":"Allenbach Y, Chaara W, Rosenzwajg M, Six A, Prevel N, Mingozzi F, Wanschitz J, Musset L, Charuel JL, Eymard B, et al. Th1 response and systemic treg deficiency in inclusion body myositis. PLoS ONE. 2014;9(3): e88788.","journal-title":"PLoS ONE"},{"issue":"8","key":"569_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"569_CR55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"key":"569_CR56","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1038\/ncomms4618","volume":"5","author":"JP Li","year":"2014","unstructured":"Li JP, Yang CY, Chuang HC, Lan JL, Chen DY, Chen YM, Wang X, Chen AJ, Belmont JW, Tan TH. The phosphatase JKAP\/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck. Nat Commun. 2014;5:3618.","journal-title":"Nat Commun"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-023-00569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-023-00569-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-023-00569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:13:32Z","timestamp":1700406812000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-023-00569-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s12865-023-00569-w","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"31 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the China Medical University Hospital (CMUH104-REC3-093). The informed consent form was obtained from each participant according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}